PMH7 TREATMENT DURATION WITH ORAL AND LONG ACTING INJECTABLE FORMULATIONS OF TYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA RESULTS ACROSS WORLD GEOGRAPHIES  by Zhu, B et al.
6 different arms (placebo; DXT-40 mg/day; DXT-60 mg/day;
DXT-80 mg/day; DXT-120 mg/day; and paroxetine [PXT]-
20 mg/day), were extracted and further combined by using 3
different random effects models (logistic regression with random
intercepts [LR-RE(1)], logistic regression with random intercepts
and slopes [LR-RE(2)], and fully random Bayesian models
[Bayes]). RESULTS: The remission rates for DXT-40 and
DXT-60 were not signiﬁcantly different to those of placebo
(upper estimates DXT-40 odds ratio [OR] = 1.27 [95%
CI = 0.84 to 1.92, LR-RE(2) model]; DXT-60 OR = 1.49 [95%
CI = 0.83 to 2.79, Bayes model]). The remission rates for DXT-
80, DXT-120, and PXT-20 were signiﬁcantly superior to placebo
(upper estimates DXT-80 OR = 1.95 [95% CI = 1.45 to 2.64,
LR-RE(2) model]; DXT-120 OR = 2.15 [95% CI = 1.46 to 3.18,
LR-RE(2) model]; and PXT-20 OR = 1.84 [95% CI = 1.34 to
2.52, LR-RE(2) model]). CONCLUSION: It is likely that higher
doses of duloxetine than those currently recommended for the
treatment of MD in the information package would be needed to
attain effective symptomatic remission. Since all the RCTs fol-
lowed a common protocol but the tested dosage, there appears
an important exchangeability among the studies, and a close
overlap among the estimates obtained from the random effects
models, and the estimates yielded by simpler ﬁxed effects models
(non reported here). In fact, a modelling approach would support
the results obtained by the ﬁxed effects models as the most
parsimonious in this case.
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OBJECTIVES: To compare the time to all-cause discontinua-
tion of ﬁrst-generation antipsychotics—in oral versus long
acting injectable (“depot”) formulation—in the usual care of
schizophrenia patients across three different countries: United
States, UK, and Australia. METHODS: We used pooled data
from a large prospective observational non-interventional study
of patients treated for schizophrenia and related disorder in
the U.S., U.K., and Australia, conducted between July 1997–
September 2003 (The Schizophrenia Care and Assessment
Program, SCAP). The analytical sample included outpatients
who initiated haloperidol, ﬂuphenazine, or zuclopenthixol in
oral or long-acting injectable formulations (N = 477). Time to
medication discontinuation for any cause during the 1-year
post initiation was compared between the oral and long-acting
injectable formulation groups using Kaplan Meier survival
analysis and Cox proportional hazard model adjusted for avail-
able patient characteristics. RESULTS: During the 1-year fol-
lowing medication initiation, patients treated with ﬁrst-
generation long-acting injectable antipsychotics were twice as
likely to stay on the medication compared to patients treated
with oral formulations (Hazard Ratio = 2.1, 95% Conﬁdence
Interval 1.5, 2.8, p < 0.001), driven mainly by the differences
between the oral and the long-acting injectable formulations of
haloperidol and zuclopenthixol. No signiﬁcant differences were
observed between the oral and the long-acting injectable
formulations of ﬂuphenazine. Overall, a greater proportion of
depot-treated patients have continued on their medication com-
pared to patients treated with only oral formulations (e.g.,
61.7% vs. 49.8% at 6 months; 48.4% vs. 35.6% at 12
months). Sensitivity analyses indicated that ﬁndings were
robust. CONCLUSION: Treatment duration- often considered
a measure reﬂecting a medication’s efﬁcacy, safety, and
tolerability—appears signiﬁcantly longer for patients treated
with long-acting injectable formulations than oral formulation
of the same ﬁrst-generation antipsychotic, suggesting that long-
acting injectable formulations offer a meaningful adherence
advantage in the treatment of patients at high risk of medica-
tion nonadherence.
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OBJECTIVES: To assess the outcome in the Canadian patients
in the electronic-Schizophrenia Treatment Adherence Registry
(e-STAR) who have been followed for at least 3-months, with
particular focus on changes in hospitalization, disease severity
and functioning after initiating risperidone long-acting injection
(RLAI). METHODS: E-STAR, is a secure web-based, interna-
tional, observational study of patients with schizophrenia who
have been initiated with RLAI. Data are collected both retro-
spectively (1 year) and prospectively (2 years) and include
hospitalisations and reasons for treatment initiation and discon-
tinuation; patients are evaluated using the Clinical Global
Impression Severity Scale (CGI-S) and Global Assessment of
Functioning Scale (GAF). RESULTS: A total of 123 patients
have been enrolled and 51 patients have been followed for 3
months. Of the 51 patients, the majority were male (66.7%)
diagnosed with schizophrenia or schizoaffective disorder
(76.5%, 15.7% respectively), mean age of 40.3  13.1 years,
and mean time since diagnosis of 11  11.1 years. The most
important reasons for switching to RLAI were poor compliance
on previous treatment (31.4%), maintenance (23.5%) and
insufﬁcient response to previous medication (17.6%). At
3-months, 98% of patients were still on RLAI treatment. Com-
paring this initial 3-month prospective period for these 51
patients to the 3-month retrospective period prior to the initia-
tion of RLAI, signiﬁcant decreases were seen in the proportion
of patients hospitalized (33.3 vs. 15.7, p = 0.013) and the
mean number of hospitalizations per patient (0.41 vs 0.16,
p = 0.006). The mean number of days in hospital decreased (6
vs. 4 days), but did not reach statistical signiﬁcance (p = 0.30).
By 3-months, there were improvements in the average CGI-S
score (4.00 to 3.86, p = 0.418) and signiﬁcant improvements in
GAF score (46.9 to 51.6, p = 0.008) compared to baseline.
CONCLUSION: Based on 3-month interim results, treatment
with RLAI was associated with a decrease in hospitalizations,
and improvements in disease severity and functioning in
patients with schizophrenia.
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